$ELDN
Eledon Pharmaceuticals, Inc.

2024 Q1 Form 10-K Financial Statement

#000095017024038091 Filed on March 28, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.459M $3.271M $12.69M
YoY Change 15.42% 17.24% -0.09%
% of Gross Profit
Research & Development $7.410M $7.067M $30.31M
YoY Change -8.67% -2.52% 11.94%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $10.87M $10.34M $43.00M
YoY Change -2.17% 2.97% -51.37%
Operating Profit -$10.87M -$43.00M
YoY Change -2.17% -51.37%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $574.0K $712.0K $2.674M
YoY Change 69.82% 134.21% 478.79%
Pretax Income -$10.30M -$9.626M -$40.33M
YoY Change -4.43% -83.51% -54.16%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$10.30M -$9.626M -$40.33M
YoY Change -4.43% -83.51% -54.16%
Net Earnings / Revenue
Basic Earnings Per Share -$0.34 -$1.64
Diluted Earnings Per Share -$0.34 -$0.32 -$1.64
COMMON SHARES
Basic Shares Outstanding 24.81M 24.20M 24.62M
Diluted Shares Outstanding 29.99M 24.62M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $42.86M $51.10M $51.10M
YoY Change -7.79% -9.41% -9.41%
Cash & Equivalents $5.655M $4.612M $4.612M
Short-Term Investments $37.21M $46.49M $46.49M
Other Short-Term Assets $54.00K $5.027M $5.027M
YoY Change 14.89% 17853.57% 61.69%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $47.98M $56.13M $56.13M
YoY Change -1.9% -5.69% -5.69%
LONG-TERM ASSETS
Property, Plant & Equipment $270.0K $365.0K $365.0K
YoY Change -58.27% -50.61% -50.61%
Goodwill $0.00
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $185.0K $186.0K $186.0K
YoY Change -49.86% 24.0% 24.0%
Total Long-Term Assets $32.84M $32.94M $32.94M
YoY Change -1.68% -1.02% -1.02%
TOTAL ASSETS
Total Short-Term Assets $47.98M $56.13M $56.13M
Total Long-Term Assets $32.84M $32.94M $32.94M
Total Assets $80.82M $89.07M $89.07M
YoY Change -1.81% -4.02% -4.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.864M $967.0K $967.0K
YoY Change -34.64% -56.05% -56.05%
Accrued Expenses $2.383M $2.928M $2.928M
YoY Change -9.25% -31.51% -31.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.247M $3.895M $3.895M
YoY Change -22.47% -39.85% -39.85%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.247M $3.895M $3.895M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $5.999M $5.647M $5.647M
YoY Change -20.16% -34.41% -34.41%
SHAREHOLDERS EQUITY
Retained Earnings -$253.5M -$243.2M
YoY Change 18.68% 19.86%
Common Stock $328.3M $326.6M
YoY Change 13.83% 13.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $74.82M $83.42M $83.42M
YoY Change
Total Liabilities & Shareholders Equity $80.82M $89.07M $89.07M
YoY Change -1.81% -4.02% -4.02%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$10.30M -$9.626M -$40.33M
YoY Change -4.43% -83.51% -54.16%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$8.741M -$9.127M -$39.53M
YoY Change -11.92% -3.72% 39.06%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $9.783M $10.07M -$45.29M
YoY Change
Cash From Investing Activities $9.783M $10.07M -$45.29M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $33.02M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.000K -3.000K 33.02M
YoY Change
NET CHANGE
Cash From Operating Activities -8.741M -9.127M -39.53M
Cash From Investing Activities 9.783M 10.07M -45.29M
Cash From Financing Activities 1.000K -3.000K 33.02M
Net Change In Cash 1.043M 943.0K -51.80M
YoY Change -110.51% -109.95% 82.23%
FREE CASH FLOW
Cash From Operating Activities -$8.741M -$9.127M -$39.53M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001404281
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-36620
CY2023 dei Entity Registrant Name
EntityRegistrantName
ELEDON PHARMACEUTICALS, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-1000967
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
19900 MacArthur Boulevard
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 550
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Irvine
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92612
CY2023 dei City Area Code
CityAreaCode
(949)
CY2023 dei Local Phone Number
LocalPhoneNumber
238-8090
CY2023 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2023 dei Trading Symbol
TradingSymbol
ELDN
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
25607310
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24813130
CY2023 dei Auditor Firm
AuditorFirmId
170
CY2023 dei Auditor Name
AuditorName
KMJ Corbin & Company LLP
CY2023 dei Auditor Location
AuditorLocation
Irvine, California
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4612000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56409000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
46490000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5027000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3109000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
56129000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
59518000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
365000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
739000
CY2023Q4 eldn In Process Research And Development
InProcessResearchAndDevelopment
32386000
CY2022Q4 eldn In Process Research And Development
InProcessResearchAndDevelopment
32386000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
186000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
150000
CY2023Q4 us-gaap Assets
Assets
89066000
CY2022Q4 us-gaap Assets
Assets
92793000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
967000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2200000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
383000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
363000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2545000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
3912000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3895000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6475000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1752000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1752000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
383000
CY2023Q4 us-gaap Liabilities
Liabilities
5647000
CY2022Q4 us-gaap Liabilities
Liabilities
8610000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24213130
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24213130
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13776788
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13776788
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
24000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
14000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
326586000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
287034000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-243191000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-202865000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
83419000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
84183000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
89066000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
92793000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30312000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27080000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12688000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12700000
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
48648000
CY2023 us-gaap Operating Expenses
OperatingExpenses
43000000
CY2022 us-gaap Operating Expenses
OperatingExpenses
88428000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-43000000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-88428000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2674000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
462000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40326000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-87966000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-40326000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-87966000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.64
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.64
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.16
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.16
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24619197
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24619197
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14285254
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14285254
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
163995000
CY2022 eldn Cancellation Of Common Stock In Exchange For Preferred Stock Value
CancellationOfCommonStockInExchangeForPreferredStockValue
1000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8153000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-87966000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
84183000
CY2023 eldn Issuance Of Common Stock In Connection With Private Investment In Public Equity Transaction Net Of Issuance Costs Value
IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue
33017000
CY2023 eldn Issuance Of Common Stock In Connection With Conversion Of X1 Non Voting Convertible Preferred Stock Value
IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue
-1000
CY2023 eldn Issuance Of Common Stock In Connection With Exercise Of Pre Funded Warrants Value
IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue
1000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6545000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-40326000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
83419000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-40326000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-87966000
CY2023 eldn Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
374000
CY2022 eldn Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
373000
CY2023 eldn Accretion On Investment Discounts
AccretionOnInvestmentDiscounts
-1203000
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
48648000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6545000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8153000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1954000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-654000
CY2023 eldn Accounts Payable Accrued Expenses And Other Liabilities
AccountsPayableAccruedExpensesAndOtherLiabilities
-2600000
CY2022 eldn Accounts Payable Accrued Expenses And Other Liabilities
AccountsPayableAccruedExpensesAndOtherLiabilities
2081000
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-363000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-367000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39527000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28424000
CY2023 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
78287000
CY2023 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
33000000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-45287000
CY2023 eldn Proceeds From Issuance Of Common Stock And Pre Funded Warrants Net
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet
33017000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
33017000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-51797000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-28424000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56409000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84833000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4612000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56409000
CY2023 eldn Common Stock Exchanged For X And X One Non Voting Convertible Preferred Stock
CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock
1000
CY2022 eldn Common Stock Exchanged For X And X One Non Voting Convertible Preferred Stock
CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock
1000
CY2022 eldn Increase Decrease In Operating Lease Asset And Liability Due To Lease Modification
IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToLeaseModification
344000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-40300000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-243200000
CY2023Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
51100000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to stock-based compensation, accruals for liabilities, impairment of long-lived assets, and other matters that affect the consolidated financial statements and related disclosures. Actual results could differ materially from those estimates under different assumptions or conditions and the differences may be material to the consolidated financial statements.</span></p>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject the Company to significant concentration of credit risk consists of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured institutions in excess of federally insured limits and invests in short-term investments with the primary objective of seeking to preserve principal, achieve liquidity requirements and safeguard invested funds. We believe that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held and the nature, including the credit ratings, of our cash equivalents and short-term investments, but we have not eliminated all credit risk.</span></p>
CY2023 eldn Cash Cash Equivalents And Restricted Cash Maturity Period
CashCashEquivalentsAndRestrictedCashMaturityPeriod
three months or less
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023 us-gaap Number Of Reporting Units
NumberOfReportingUnits
1
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
48600000
CY2022Q4 us-gaap Goodwill
Goodwill
0
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-40326000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-87966000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.64
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.64
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.16
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.16
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24619197
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24619197
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14285254
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14285254
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33486487
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8139156
CY2023 eldn Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Taxes Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxesExpenseBenefit
0
CY2023 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement.
CY2023Q4 eldn Income Tax Examination Likelihood Of Favorable Settlement
IncomeTaxExaminationLikelihoodOfFavorableSettlement
0.50
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
46490000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
46490000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
0
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
624000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
823000
CY2023Q4 eldn Prepaid Clinical Expense
PrepaidClinicalExpense
4128000
CY2022Q4 eldn Prepaid Clinical Expense
PrepaidClinicalExpense
2115000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
185000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
143000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
90000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
28000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5027000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3109000
CY2023Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
2003000
CY2022Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1909000
CY2023Q4 eldn Accrued Clinical Current
AccruedClinicalCurrent
451000
CY2022Q4 eldn Accrued Clinical Current
AccruedClinicalCurrent
1826000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
47000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
65000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
44000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
112000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2545000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
3912000
CY2021Q4 us-gaap Goodwill
Goodwill
48648000
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
48648000
CY2022Q4 us-gaap Goodwill
Goodwill
0
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023Q4 us-gaap Goodwill
Goodwill
0
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
CY2023 eldn Lessee Operating Lease Remaining Term Of Contract
LesseeOperatingLeaseRemainingTermOfContract
P12M
CY2023Q4 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
0
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
400000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
403000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
378000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
387000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
344000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y11M12D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y11M12D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0249
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0249
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
388000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
388000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
383000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
383000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2023Q4 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2023Q4 eldn Contingent Liability
ContingentLiability
0
CY2022Q4 eldn Contingent Liability
ContingentLiability
0
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-40525000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-88159000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
199000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
193000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40326000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-87966000
CY2023 eldn Effective Federal And State Income Tax Rate
EffectiveFederalAndStateIncomeTaxRate
0.21
CY2022 eldn Effective Federal And State Income Tax Rate
EffectiveFederalAndStateIncomeTaxRate
0.21
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-8468000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-18473000
CY2023 eldn State Income Taxes Net Of Federal Tax Benefits
StateIncomeTaxesNetOfFederalTaxBenefits
-1097000
CY2022 eldn State Income Taxes Net Of Federal Tax Benefits
StateIncomeTaxesNetOfFederalTaxBenefits
-2678000
CY2023 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
972000
CY2022 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
1046000
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
728000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
986000
CY2023 eldn Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
9000
CY2022 eldn Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
3000
CY2023 eldn Income Tax Reconciliation State Tax Rate Differential
IncomeTaxReconciliationStateTaxRateDifferential
32000
CY2022 eldn Income Tax Reconciliation State Tax Rate Differential
IncomeTaxReconciliationStateTaxRateDifferential
274000
CY2023 eldn Nol True Up
NOLTrueUp
2000
CY2022 eldn Nol True Up
NOLTrueUp
-337000
CY2023 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
566000
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
114000
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Impairment Losses
IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
0
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Impairment Losses
IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
11697000
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
9200000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
9460000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
18089000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
15230000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3202000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2294000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
475000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
452000
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
10567000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
5264000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3085000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2874000
CY2023Q4 eldn Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
1319000
CY2022Q4 eldn Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
1595000
CY2023Q4 eldn Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
91000
CY2022Q4 eldn Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
179000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
36828000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
27888000
CY2023Q4 eldn Deferred Tax Assets Right Of Use Asset
DeferredTaxAssetsRightOfUseAsset
87000
CY2022Q4 eldn Deferred Tax Assets Right Of Use Asset
DeferredTaxAssetsRightOfUseAsset
178000
CY2023Q4 eldn Deferred Tax Liabilities In Process Research And Development
DeferredTaxLiabilitiesInProcessResearchAndDevelopment
7682000
CY2022Q4 eldn Deferred Tax Liabilities In Process Research And Development
DeferredTaxLiabilitiesInProcessResearchAndDevelopment
7787000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
7769000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
7965000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
30811000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
21675000
CY2023Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1752000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1752000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2664000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1469000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
972000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
914000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
281000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
3636000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2664000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9100000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9100000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9400000
CY2023 eldn Period For Which Cumulative Change In Ownership Annual Use Net Operating Loss And Research And Development Credit Carryforwards
PeriodForWhichCumulativeChangeInOwnershipAnnualUseNetOperatingLossAndResearchAndDevelopmentCreditCarryforwards
P3Y
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
21564302
CY2023 eldn Number Of Specific Clinical Development Milestones Achieved
NumberOfSpecificClinicalDevelopmentMilestonesAchieved
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4213977
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.33
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M24D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1267700
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.81
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
263644
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
12.12
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5218033
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.69
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
11026451
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.10
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
862631
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
8.07
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
15381853
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.21
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
235000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
9476369
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.40
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y2M12D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
235000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4065023
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.54
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.905
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.839
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.037
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.02
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M7D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.6
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.76
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6545000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8153000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
12400000
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M24D

Files In Submission

Name View Source Status
0000950170-24-038091-index-headers.html Edgar Link pending
0000950170-24-038091-index.html Edgar Link pending
0000950170-24-038091.txt Edgar Link pending
0000950170-24-038091-xbrl.zip Edgar Link pending
eldn-20231231.htm Edgar Link pending
eldn-20231231.xsd Edgar Link pending
eldn-ex10_22.htm Edgar Link pending
eldn-ex10_23.htm Edgar Link pending
eldn-ex23_1.htm Edgar Link pending
eldn-ex31_1.htm Edgar Link pending
eldn-ex31_2.htm Edgar Link pending
eldn-ex32_1.htm Edgar Link pending
eldn-ex32_2.htm Edgar Link pending
eldn-ex97_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img116206746_0.jpg Edgar Link pending
img116206746_1.jpg Edgar Link pending
img116206746_2.jpg Edgar Link pending
img116206746_3.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
eldn-20231231_htm.xml Edgar Link completed
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending